LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Patients with an Advanced Solid Tumor
Contact:
NCT Number:
Protocol:
AAAT7518
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/II
The purpose of this study is to test the safety of the experimental drugs called 68Ga-FAP-2286 and 177Lu-FAP-2286. 8Ga-FAP-2286 is an imaging agent that targets a certain protein which has been found in certain tumors called Fibroblast activation protein (FAP). Imaging using 68Ga-FAP-2286 will determine if participants are eligible to receive the experimental radiotherapy, 177Lu-FAP-2286, which researchers think may kill cancer cells by delivering radiation to cancer cells that have fibroblast activation protein (FAP).
Are you Eligible? (Inclusion Criteria)
- Have you been diagnosed with advanced or metastatic cancer?
- Has your cancer progressed from prior treatment?
- Are you aged 18 years or older?
Specialty Area(s)
Bladder Cancer , Breast Cancer, Colon and Rectal Cancer, Esophageal Cancer, Gynecologic Cancers, Head and Neck/Oral Cancers, Kidney Cancer/Adrenal Cancer, Liver Cancer, Lung cancer, Skin cancers, Melanoma, Pancreatic Cancer, Prostate Cancer, Sarcomas (Bone and Soft Tissue), Stomach Cancer, Testicular Cancer, Thyroid Cancer
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
